Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 7968 publications.

Jimenez M, Zanotti G, Parikh RC, Esterberg E, Suarez LA. A retrospective medical record review of first-line sunitinib administration schedules and outcomes among patients with metastatic renal cell carcinoma in Latin America. Poster to be given at the ISPOR 2023 Conference; May 9, 2023.

Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster to be given at the ISPOR 2023 Conference; May 9, 2023. Boston, MA.

Willke R, McElwee N, Cole A, Berger M, Earnshaw S. Towards broader relevance for HEOR: an HSPC visioning project. Presentation to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Mordin M, Castro C, Gnanasakthy A. Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022). Poster to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderas M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S. Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. Poster to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Karcher H, Hawe E, Gatto N, Jonsson P. External control arms (ECA) in phase 3 trials: what is needed now and in the future to enable acceptance with regulatory and HTA bodies? Presentation to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Kosa K, Mutebi A, Wang A, Blaedel J, Sacchi M, Martin S. Improvements in symptoms, impact of treatment, and satisfaction with treatment among patients with relapsed or refractory b-cell non-hodgkin lymphoma treated with subcutaneous epcoritamab. Poster to be given at the ISPOR 2023 Conference; May 8, 2023. Boston, MA.

Aris E, Brabant Y, La E, Candrilli S, Molnar D. Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: a retrospective claims database analysis. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Dong O, Purser M, Herring WL, Mladsi (she/her) DM, Gallagher M, Chawla A, Leiding JW, Andemariam B. Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C. Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Hundt Golden A, Gabriel MH, Price M. The Delphi Panel—from discord to actionable HEOR insights. Presentation to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster to be given at the ISPOR 2023 Conference; May 7, 2023.

Poulos C, Mansfield C, Bussberg CJ, Hicks JC, Downey C. Advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference research. Poster to be given at the ISPOR 2023 Conference; May 7, 2023.

Poulos C, Pierce A, Chintakayala PK. A review of the influence of stakeholder preference research on the EtR framework. Poster to be given at the ISPOR 2023 Conference; May 7, 2023.

Houghton K, Hitchens A, Ciepielewska M. Healthcare resource use and costs among patients with erythropoietic protoporphyria and x-linked protoporphyria in the United States. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Janssen E, Smith I, Liu X, Mansfield C, Pierce A, Huang Q, Kalsekar I. Patient preferences for lung cancer interception therapy. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N. Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

McMichael A, Poulos C, Vass C, Boeri M. A literature review assessing the most common attributes used in stated-preference studies assessing influenza vaccination: do we know what health care professionals value? Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Fernandez M, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Burden of surgery in desmoid tumors. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Gohil S, Johnson ML, Goyal R. Impact of a cancer diagnosis on non-cancer chronic disease medication adherence - a systematic literature review. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Frederiksen KS, Crawford R, Hahn-Pedersen JH, Morrison R, Jeppesen R, Doward L, Weidner W. Insights from social media posts on the lived experience of alzheimer's disease. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Johnson ML, Yande S, Aparasu RR, Wanat M, Toale K. Prevalence and factors associated with the use of direct oral anticoagulants and Low Molecular Weight Heparins (LMWH) in cancer patients. Poster to be given at the ISPOR 2023 Conference; May 7, 2023. Boston, MA.

Yousif Z, Schultz BG, Candela N, Harold S, Bell J, Turpin R, Hartley L. Systematic literature review to evaluate randomized clinical trials of advanced therapies for moderate to severe crohn's disease. Poster to be given at the ISPOR 2023 Conference; May 6, 2023. Boston, MA.

Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster to be given at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349

Lin S, Kahangire DA, Nagar S, Ahn M, Affi R, Agulnik J, Shih J, Hockmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M, Davis KL, Sandelin M, Veluswamy R. Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study. Poster to be given at the European Lung Cancer Congress 2023; March 31, 2023. Copenhagen, Demark.

Simmons DJ, Blank SV, Nagar S, Nham T, Long GH, Davis KL, Wetherill G, Munley J, McLaurin K. Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: retrospective US cohort study. Poster presented at the SGO 2023 Annual Meeting on Women's Cancer; March 27, 2023. Tampa, FL.

Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Webster M, Haqq AM, Haws RM. Interview-based patient- and caregiver-reported experiences of hunger and improved quality of life with setmelanotide treatment in bardet-biedl syndrome. Adv Ther. 2023 Mar 24. doi: 10.1007/s12325-023-02443-y

Khan AH, Kosa K, De Prado Gomez L, Whalley D, Kamat S, Clark M. Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, uncontrolled asthma. Patient Relat Outcome Meas. 2023 Mar 23;14:57-71. doi: 10.2147/PROM.S392666

Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design considerations for observational studies of drugs for advanced cancer . Pharmacoepidemiol Drug Saf. 2023 Mar 15. doi: 10.1002/pds.5612

Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Marshall G. Knowledge of invasive meningococcal disease and vaccination recommendations for adolescents and young adults among US physicians. Poster presented at the SAHM 2023 Annual Meeting; March 7, 2023. Baltimore, MD.

Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Marshall G. Physician communication with patients/parents on MenB vaccination for older adolescents and young adults. Poster presented at the SAHM 2023 Annual Meeting; March 7, 2023. Baltimore, MD.

Curran D, Patterson BJ, Carrico J, Salem A, La EM, Lorenc Stephane, Hicks KA, Poston S, Carpenter CF. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. Hum Vaccin Immunother. 2023 Mar 7. doi: 10.1080/21645515.2023.2167907

Chinthammit C, Mody R, Aguado J, Meyers J. Does weight loss in addition to HbA1c reduction impact health care costs in patients treated with T2D? a retrospective database analysis. Poster presented at the AMCP 2023 Annual Meeting; March 21, 2023. San Antonio, TX. [abstract] J Manag Care Pharm. 2023 Mar; 29(10-2):S27.

DeMuro C, Finelli L, Lewis S, Williams V, Martin E, Phillips M, Saretsky T, Osborne R, Norquist J. Assessing the patient experience of respiratory syncytial virus infection: development of a patient-reported outcome measure. Health Qual Life Outcomes. 2023 Feb 28;21(1):20. doi: 10.1186/s12955-022-02066-x

Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 Feb 28. doi: 10.1200/OP.22.00774

Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470

Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Talbird S, Cook C, DeMartino J, Hernandez-Pastor L, Krishnarajah G. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Sauchelli S, Pickles T, Voinescu A, Choi H, Sherlock B, Zhang J, Colyer S, Grant S, Sundari S, Lasseter G. Public attitudes towards the use of novel technologies in their future healthcare: a UK survey. BMC Med Inform Decis Mak. 2023 Feb 22;23(1):38. doi: 10.1186/s12911-023-02118-2

Grace M, Costello J, Colosia A, Wolowacz S, Panozzo CA, Ghaswalla P. Economic and health-related quality of life burden in adults with RSV: a systematic literature review and gap analysis. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Parikh RC, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Respiratory syncytial virus–attributable hospitalizations among adults ≥60 years in the United States – a comparison by race/ethnicity. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Parikh RC, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Respiratory syncytial virus versus influenza hospitalizations among adults ≥60 years in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):661. doi: 10.1200/JCO.2023.41.6_suppl.661

Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient and physician preferences for adjuvant treatment of renal cell carcinoma: a discrete-choice experiment. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):635. doi: 10.1200/JCO.2023.41.6_suppl.635

DiBenedetti D, Menne H, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Heithoff K, Hartry A, Oberdhan D, Wilson H, Hoffman DL, Weinberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Hauber B, Romano (DeMuro) C. Technical review of clinical outcomes assessments across the continuum of Alzheimer's disease. Neurol Ther. 2023 Feb 15. doi: 10.1007/s40120-023-00443-2

Martin S, Bender R, Krasner A, Marmon T, Monahan M, Nelson L. Development and evaluation of the acromegaly symptom diary. J Patient Rep Outcomes. 2023 Feb 15;7(1):15. doi: 10.1186/s41687-023-00541-7

Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Feb 12;12:1-18. doi: 10.1007/s40121-023-00767-4